Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Valeant will reach 100 $ again
View:
Post by fundtrader on May 15, 2016 12:11pm

Valeant will reach 100 $ again

Why ...??? The shares have been rolled over to new owners now at the lowest levels possible. The losers have changed hands to new buyers who continue to buy at these levels.. Reasons for move up.. 1) 11 billion in revenues 2) Free Cash Flow 3) Sell of Assets to reduce Debts 4) NEW CEO and new focus to improve company 5) Company has over 300 drugs and more in pipeline 6) Solid franchises like Bausch and Lomb, Dermatology, Salix etc etc.. 7) Week on week scripts and improving I wont be surprised to see a double from these levels.. Will easily reach 60 $ I think in 6 mths..buying more daily...
Comment by Marky1 on May 15, 2016 1:18pm
Well said Funtrader! I agree with you fully..Other points to consider..People need our products and will continue to use them...The population is getting larger and people are ageing,resulting in more medications being prescribed...Walmart deal which started in January will increase their earnings..At this time All the pharmaceuticals are doing poorly in the market, so it's not any longer only ...more  
Comment by Joe454 on May 15, 2016 2:01pm
This post has been removed in accordance with Community Policy
Comment by fundtrader on May 15, 2016 4:12pm
Just floating Bausch and lomb can wipe out 5 billion in debt..I don't think its a big issue as the revenue is over 11 billion $ Free cash flow over 2 billion after all payments. Dont forget they got enough assets they can sell to reduce this debt easily. They probably could be taken out for over 60 $ us a share.. Allergan, Johnson and Johnson , etc can all use their high share price to take ...more  
Comment by DoubleDown123 on May 15, 2016 5:06pm
There is no disputing their ability to meet debt obligations now according to year end financials and current guidance, the big uncertainty is how exisiting cash flow will be affected going forward. Assuming the acquisition model previously employed is no longer feasible due to price regulations, Valeant will have to become more like a traditional pharma company spending ...more  
Comment by kingsooriyassc2 on May 15, 2016 2:25pm
new ceo not interesting to sale assets he mostly focus on change administration lines.even that's good thing 4 this company back on.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities